These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8115987)

  • 1. A quantitative thrombin time for determining levels of hirudin and Hirulog.
    Reid TJ; Alving BM
    Thromb Haemost; 1993 Oct; 70(4):608-16. PubMed ID: 8115987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene.
    Rubens FD; Weitz JI; Brash JL; Kinlough-Rathbone RL
    Thromb Haemost; 1993 Feb; 69(2):130-4. PubMed ID: 8456425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic effects of hirulog in a rat carotid endarterectomy model.
    Jackson MR; Reid TJ; Tang DB; O'Donnell SD; Gomez ER; Alving BM
    J Surg Res; 1996 Jan; 60(1):15-22. PubMed ID: 8592407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease.
    Cannon CP; Maraganore JM; Loscalzo J; McAllister A; Eddings K; George D; Selwyn AP; Adelman B; Fox I; Braunwald E
    Am J Cardiol; 1993 Apr; 71(10):778-82. PubMed ID: 8456753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin.
    Callas DD; Hoppensteadt D; Fareed J
    Semin Thromb Hemost; 1995; 21(2):177-83. PubMed ID: 7660140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans.
    Fox I; Dawson A; Loynds P; Eisner J; Findlen K; Levin E; Hanson D; Mant T; Wagner J; Maraganore J
    Thromb Haemost; 1993 Feb; 69(2):157-63. PubMed ID: 8456428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model.
    Deschênes I; Finkle CD; Winocour PD
    Thromb Haemost; 1998 Jul; 80(1):186-91. PubMed ID: 9684808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog.
    Chamberlin JR; Lewis B; Leya F; Wallis D; Messmore H; Hoppensteadt D; Walenga JM; Moran S; Fareed J; McKiernan T
    Can J Cardiol; 1995 Jun; 11(6):511-4. PubMed ID: 7780873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay.
    Pötzsch B; Hund S; Madlener K; Unkrig C; Müller-Berghaus G
    Thromb Res; 1997 Jun; 86(5):373-83. PubMed ID: 9211628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental studies on a recombinant hirudin, CGP 39393.
    Gray E; Watton J; Cesmeli S; Barrowcliffe TW; Thomas DP
    Thromb Haemost; 1991 Apr; 65(4):355-9. PubMed ID: 2057916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects.
    Lidón RM; Théroux P; Juneau M; Adelman B; Maraganore J
    Circulation; 1993 Oct; 88(4 Pt 1):1495-501. PubMed ID: 8403297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of platelet deposition by combined hirulog and aspirin in a rat carotid endarterectomy model.
    Hamelink JK; Tang DB; Barr CF; Jackson MR; Reid TJ; Gomez ER; Alving BM
    J Vasc Surg; 1995 Mar; 21(3):492-8. PubMed ID: 7877232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombin-specific inhibition by and slow cleavage of hirulog-1.
    Witting JI; Bourdon P; Brezniak DV; Maraganore JM; Fenton JW
    Biochem J; 1992 May; 283 ( Pt 3)(Pt 3):737-43. PubMed ID: 1290488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects on thrombin generation of single injections of Hirulog in patients with calf vein thrombosis.
    Ginsberg JS; Nurmohamed MT; Gent M; MacKinnon B; Stevens P; Weitz J; Maraganore J; Hirsh J
    Thromb Haemost; 1994 Oct; 72(4):523-5. PubMed ID: 7878625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic mechanism for the interaction of Hirulog with thrombin.
    Parry MA; Maraganore JM; Stone SR
    Biochemistry; 1994 Dec; 33(49):14807-14. PubMed ID: 7993908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of hirulog in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits.
    Sarembock IJ; Gertz SD; Thome LM; McCoy KW; Ragosta M; Powers ER; Maraganore JM; Gimple LW
    J Vasc Res; 1996; 33(4):308-14. PubMed ID: 8695755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Follow-up of the treatment by direct thrombin inhibitors: activated partial thromboplastin time or ecarin clotting time].
    Kher A; Gouin I; Samama MM
    Ann Biol Clin (Paris); 2000; 58(5):575-9. PubMed ID: 11022100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis.
    Biemond BJ; Friederich PW; Levi M; Vlasuk GP; Büller HR; ten Cate JW
    Circulation; 1996 Jan; 93(1):153-60. PubMed ID: 8616922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hirudin and Hirulog.
    White H
    Aust N Z J Med; 1993 Dec; 23(6):769-70. PubMed ID: 8141724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin.
    Ofosu FA; Fenton JW; Maraganore J; Blajchman MA; Yang X; Smith L; Anvari N; Buchanan MR; Hirsh J
    Biochem J; 1992 May; 283 ( Pt 3)(Pt 3):893-7. PubMed ID: 1590777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.